microdosing glp-1 for hashimoto's Thyroid Issues: Who Should Consider It? New Hashimoto’s Treatment in 2025

This analysis of survey data finds that over 40% of adults under 65 with private insurance could be indicated for a GLP-1 drug though relatively few have a claim, suggesting that a much smaller share seeks treatment through healthcare providers.

Sustained ReleaseThe patch provides up to 24 hours of active ingredient release throughout the day, which is convenient and practical

Clinical trial data shows a 5-10 BPM increase driven by the glucagon receptor

Get updates on the Zepbound lawsuit and allegations against Eli Lilly for failure to warn about gastroparesis, ileus, and other severe side effects.

Discover differences in efficacy, side effects, and cost

Compare how they work, FDA status, weight loss, cost, and how providers choose.